BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

REPL upcoming catalysts

Replimune, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 3 FDA event(s). Subscribe to REPL (.ics).

Drugs: nivolumab

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-07-30FDA AdComheldReplimune, Inc. REPLAdCom 2026-07-30: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125827
2026-07-30FDA AdComheldReplimune, Inc. REPLAdCom 2026-07-30: Cellular, Tissue, and Gene Therapies Advisory Committee - BLA 125827
2026-04-10Complete response lettercomplete responseReplimune, Inc. REPLCRL 2026-04-10: Replimune, Inc. BL 125827

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-03-01 est.P2Replimune, Inc. REPLNCT05743270 Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNSquamous Cell Carcinoma of Head and Neck; Locally Advanced Head and Neck Squamous Cell Carcinoma; Rewithdrawn

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.